Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

FOLFOX or FOLFIRI

Phase 2Small molecule

SSt. Olavs Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColorectalRecruiting

ColorectalPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2040

Phase 2Recruiting

Colorectal

NCT06907342

Clinical

Trials by Indication[1]

Colorectal1 trial

COSENSE-1: A Feasibility Study for Using a Functional Precision Medicine Platform to Select Oxaliplatin-based Versus Irinotecan-based Chemotherapy Regimens for Patients With Metastatic Colorectal Cancer

Recruiting·SSt. Olavs Hospital·Phase 2·NCT06907342·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FOLFOX or FOLFIRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX or FOLFIRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX or FOLFIRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Olavs Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSt. Olavs Hospital

Related News